Buy & Sell HubSpot Inc (HUBS) – HubSpot Inc Price Today
Aura AI Summary
Key Stats
- $10.15BMarket Cap
- TechnologySector
- -39.64%3M Drawdown
- $8.71BEnterprise Value
- -Dividend Yield
- 85% Buy | 15% SellTrading Activity
- 63 daysTypical Hold Time
HubSpot Inc (HUBS) is currently valued at a market capitalization of $10.15B, with an enterprise value of $8.71B. Over the past 52 weeks, HubSpot Inc has traded between a low of $179 and a high of $627.8, highlighting its annual price range. Over the past three months, HubSpot Inc has recorded a drawdown of -39.64%, reflecting recent price volatility. On average, investors hold HubSpot Inc for approximately 63 days, indicating typical investor behavior on the platform.
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Most Recent News
CN Energy's Pathenbot launches intelligent robotic cargo sorting in the US with a 100,000-unit order.
CN Energy Group's subsidiary Pathenbot has signed an order to provide intelligent robotic cargo sorting services in the United States, marking the commercial launch of these services. The initial order covers 100,000 units and includes barcode scanni...

BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting
BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonst...

BioNTech reveals promising late-stage cancer drug data at ASCO 2026, advancing treatments for lung and ovarian cancers.
BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell ...
